Reference SummaryBennett LM, Cancer Res 2000 Jul 1;60(13):3461-9
Title |
Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. |
Authors |
Bennett LM; McAllister KA; Malphurs J; Ward T; Collins NK; Seely JC; Gowen LC; Koller BH; Davis BJ; Wiseman RW |
Journal |
Cancer Res |
Volume |
60 |
Issue |
13 |
Year |
2000 |
Pages |
3461-9 |
Abstract |
Women who inherit mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, are predisposed to the development of breast and ovarian cancer. We used mice with a Brca1 mutation on a BALB/cJ inbred background (BALB/cB1+/- mice) or a Brca2 genetic alteration on the 129/SvEv genetic background (129B2+/- mice) to investigate potential gene-environment interactions between defects in these genes and treatment with the highly estrogenic compound diethylstilbestrol (DES). Beginning at 3 weeks of age, BALB/cB1+/-, 129B2+/-, and wild-type female mice were fed a control diet or a diet containing 640 ppb DES for 26 weeks. DES treatment caused vaginal epithelial hyperplasia and hyperkeratosis, uterine inflammation, adenomyosis, and fibrosis, as well as oviductal smooth muscle hypertrophy. The severity of the DES response was mouse strain specific. The estrogen-responsive 129/SvEv strain exhibited an extreme response in the reproductive tract, whereas the effect in BALB/cJ and C3H/HeN(MMTV-) mice was less severe. The Brca1 and Brca2 genetic alterations influenced the phenotypic response of BALB/cJ and 129/SvEv inbred strains, respectively, to DES in the mammary gland and ovary. The mammary duct branching morphology was inhibited in DES-treated BALB/cB1+/- mice compared with similarly treated BALB/cB1+/+ littermates. In addition, the majority of BALB/cB1+/- mice had atrophied ovaries, whereas wild-type littermates were largely diagnosed with arrested follicular development. The mammary ductal architecture in untreated 129B2+/- mice revealed a subtle inhibited branching phenotype that was enhanced with DES treatment. However, no significant differences were observed in ovarian pathology between 129B2+/+ and 129B2+/- mice. These data suggest that estrogenic compounds may modulate mammary gland or ovarian morphology in BALB/cB1+/- and 129B2+/- mice. These observations are consistent with the hypothesis that compromised DNA repair processes in cells harboring Brca1 or Brca2 mutations lead to inhibited growth and differentiation compared with the proliferative response of wild-type cells to DES treatment. |
Links |
J:206999 – MGI References 10910057 – National Library of Medicine/PubMed |
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| C3H/HeN | Mammary gland adenocarcinoma |
|
Mammary gland |
14 |
|
| C3H/HeN | Mammary gland adenocarcinoma - papillary/cystic |
|
Mammary gland |
7.1 |
|
| C.129P2 | Mammary gland tumor | Mammary gland |
0 |
||
| C.129P2 | Mammary gland tumor |
|
Mammary gland |
0 |
|
| C.129P2-Brca1tm1Bhk/+ | Mammary gland tumor | Mammary gland |
0 |
||
| C.129P2-Brca1tm1Bhk/+ | Mammary gland tumor |
|
Mammary gland |
0 |
|
| 129 | Mammary gland tumor | Mammary gland |
0 |
||
| 129 | Mammary gland tumor |
|
Mammary gland |
0 |
|
| 129-Brca2tm1Mbn/+ | Mammary gland tumor | Mammary gland |
0 |
||
| 129-Brca2tm1Mbn/+ | Mammary gland tumor |
|
Mammary gland |
0 |
|
| C3H/HeN | Mammary gland tumor |
|
Mammary gland |
14 |
|
| C.129P2 | Ovary - Follicle cyst |
|
Ovary - Follicle |
9.1 |
|
| C.129P2-Brca1tm1Bhk/+ | Ovary - Follicle cyst |
|
Ovary - Follicle |
46 |
|
| 129 | Ovary - Follicle cyst |
|
Ovary - Follicle |
20 |
|
| 129-Brca2tm1Mbn/+ | Ovary - Follicle cyst |
|
Ovary - Follicle |
20 |
|
| C.129P2 | Uterus - Endometrium hyperplasia - cystic |
|
Uterus - Endometrium |
58 |
|
| C.129P2-Brca1tm1Bhk/+ | Uterus - Endometrium hyperplasia - cystic |
|
Uterus - Endometrium |
77 |
|
| 129 | Uterus - Endometrium hyperplasia - cystic |
|
Uterus - Endometrium |
14 |
|
| 129-Brca2tm1Mbn/+ | Uterus - Endometrium hyperplasia - cystic |
|
Uterus - Endometrium |
29 |
|
| C.129P2 | Uterus adenocarcinoma |
|
Uterus |
0 |
|
| C.129P2-Brca1tm1Bhk/+ | Uterus adenocarcinoma |
|
Uterus |
0 |
|
| 129 | Uterus adenocarcinoma |
|
Uterus |
14 |
|
| 129-Brca2tm1Mbn/+ | Uterus adenocarcinoma |
|
Uterus |
0 |
|
| C3H/HeN | Uterus adenocarcinoma | Uterus |
0 |
||
| C3H/HeN | Uterus adenocarcinoma |
|
Uterus |
50 |
|
| C.129P2 | Uterus carcinoma |
|
Uterus |
0 |
|
| C.129P2-Brca1tm1Bhk/+ | Uterus carcinoma |
|
Uterus |
0 |
|
| 129 | Uterus carcinoma |
|
Uterus |
7.1 |
|
| 129-Brca2tm1Mbn/+ | Uterus carcinoma |
|
Uterus |
7.1 |
|
| C.129P2 | Uterus dysplasia |
|
Uterus |
8.3 |
|
| C.129P2-Brca1tm1Bhk/+ | Uterus dysplasia |
|
Uterus |
0 |
|
| 129 | Uterus dysplasia |
|
Uterus |
36 |
|
| 129-Brca2tm1Mbn/+ | Uterus dysplasia |
|
Uterus |
36 |
|
| C.129P2 | Uterus hyperplasia |
|
Uterus |
8.3 |
|
| C.129P2-Brca1tm1Bhk/+ | Uterus hyperplasia |
|
Uterus |
23 |
|
| 129 | Uterus hyperplasia |
|
Uterus |
43 |
|
| 129-Brca2tm1Mbn/+ | Uterus hyperplasia |
|
Uterus |
36 |
|
| C.129P2 | Uterus lesion |
|
Uterus |
0 |
|
| C.129P2-Brca1tm1Bhk/+ | Uterus lesion |
|
Uterus |
0 |
|
| 129 | Uterus lesion |
|
Uterus |
7.1 |
|
| 129-Brca2tm1Mbn/+ | Uterus lesion |
|
Uterus |
43 |
|
| C.129P2 | Uterus metaplasia |
|
Uterus |
0 |
|
| C.129P2-Brca1tm1Bhk/+ | Uterus metaplasia |
|
Uterus |
0 |
|
| 129 | Uterus metaplasia |
|
Uterus |
7.1 |
|
| 129-Brca2tm1Mbn/+ | Uterus metaplasia |
|
Uterus |
7.1 |
|
| C.129P2 | Uterus metaplasia - squamous |
|
Uterus |
0 |
|
| C.129P2-Brca1tm1Bhk/+ | Uterus metaplasia - squamous |
|
Uterus |
0 |
|
| 129 | Uterus metaplasia - squamous |
|
Uterus |
14 |
|
| 129-Brca2tm1Mbn/+ | Uterus metaplasia - squamous |
|
Uterus |
14 |
|
| C.129P2 | Uterus squamous cell carcinoma |
|
Uterus |
0 |
|
| C.129P2-Brca1tm1Bhk/+ | Uterus squamous cell carcinoma |
|
Uterus |
0 |
|
| 129 | Uterus squamous cell carcinoma |
|
Uterus |
7.1 |
|
| 129-Brca2tm1Mbn/+ | Uterus squamous cell carcinoma |
|
Uterus |
7.1 |
|
| C.129P2 | Vagina hyperplasia |
|
Vagina |
36 |
|
| C.129P2-Brca1tm1Bhk/+ | Vagina hyperplasia |
|
Vagina |
38 |
|
| 129 | Vagina hyperplasia |
|
Vagina |
36 |
|
| 129-Brca2tm1Mbn/+ | Vagina hyperplasia |
|
Vagina |
29 |
|
| C.129P2 | (Unspecified organ) hyperplasia - squamous |
|
(Unspecified organ) |
0 |
|
| C.129P2-Brca1tm1Bhk/+ | (Unspecified organ) hyperplasia - squamous |
|
(Unspecified organ) |
0 |
|
| 129 | (Unspecified organ) hyperplasia - squamous |
|
(Unspecified organ) |
7.1 |
|
| 129-Brca2tm1Mbn/+ | (Unspecified organ) hyperplasia - squamous |
|
(Unspecified organ) |
14 |
|
| C.129P2 | (Unspecified organ) squamous cell carcinoma |
|
(Unspecified organ) |
9.1 |
|
| C.129P2-Brca1tm1Bhk/+ | (Unspecified organ) squamous cell carcinoma |
|
(Unspecified organ) |
0 |
|
| 129 | (Unspecified organ) squamous cell carcinoma |
|
(Unspecified organ) |
0 |
|
| 129-Brca2tm1Mbn/+ | (Unspecified organ) squamous cell carcinoma |
|
(Unspecified organ) |
0 |
|
| C3H/HeN | (Unspecified organ) squamous cell carcinoma | (Unspecified organ) |
0 |
||
| C3H/HeN | (Unspecified organ) squamous cell carcinoma |
|
(Unspecified organ) |
7.1 |